GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02536339
- Locations
- 🇺🇸
Temple Cancer Center; Oncology, Philadelphia, Pennsylvania, United States
🇺🇸Methodist Hospital Research Institute, Houston, Texas, United States
🇺🇸Dana Farber Cancer Inst., Boston, Massachusetts, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02528903
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec, Canada
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT02510794
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸N CA Retina Vitreous Assoc, Mountain View, California, United States
🇺🇸Retina Research Center, Austin, Texas, United States
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT02500407
- Locations
- 🇬🇧
Barts Cancer Institute, London, United Kingdom
🇬🇧Royal Marsden Hospital; Institute of Cancer Research; Pharmacy Stores, Sutton, United Kingdom
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT02486809
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT02471846
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02471859
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02457793
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02427243
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT02410512
- Locations
- 🇫🇷
Gustave Roussy, Villejuif CEDEX, France
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇺🇸University of Colorado, Aurora, Colorado, United States